Magnetic screening nanoplatform for identifying GLUT5 inhibitors or activators

Overview

This solution is a magnetic screening nanoplatform that uses cell-membrane-coated magnetic nanoparticles to identify compounds binding to GLUT5, a glucose transporter implicated in fructose metabolism and metabolic disease. Functional GLUT5 receptors embedded in native cell membrane fragments serve as biological "fishing baits" to capture binding compounds from complex mixtures such as plant extracts or drug libraries. The magnetic core enables rapid isolation of bound compounds, streamlining hit identification for metabolic disease therapeutics and functional food research. The platform is relevant to the broader pharmaceutical market, where over 60% of drugs target membrane proteins.

Technical specifications

Core design:

• Magnetic nanoparticles approximately 250 nm in diameter
• Cell membrane fragments with upregulated GLUT5 receptors fully coating the nanoparticle surface
• Membrane coating preserves the native lipid bilayer environment, maintaining proper GLUT5 conformation and binding function

Screening workflow:

• Cell membrane fragments are prepared from GLUT5-upregulated cell lines (HepG2 and trained PC-3 cells)
• Membranes are coated onto magnetic nanoparticles using established protocols
• The platform is incubated with compound mixtures; bound compounds are magnetically isolated and identified
• Identified hits are validated using cellular assays to confirm GLUT5 inhibitory or activating activity

Performance validation:

• Detection limit and median binding concentration evaluated against known GLUT5 modulators
• Screening targets can be switched to other membrane proteins, such as SGLT1, by substituting the source cell line

Prior proof-of-concept:

• Validated with α3β4 nicotinic receptors to identify compounds from smoke condensates
• Validated with TrkB receptors to identify TrkB-binding compounds from plant extracts and drug libraries, with biological activity confirmed in primary neurons

Technology readiness level

The underlying cell-membrane-coated magnetic nanoparticle platform has demonstrated proof-of-concept across multiple transmembrane receptor targets. GLUT5-specific validation is in progress, with planned steps including platform generation using GLUT5-upregulated cell lines, analytical benchmarking against known GLUT5 modulators, and screening of plant extracts with downstream cellular confirmation. The platform is ready for collaborative optimization and application to additional membrane protein targets.